Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS J GEORGE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1104867365
CMS profile
321938
Location
GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$299.42

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $299.42 5

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $134.70 1
MAYNE PHARMA COMMERCIAL LLC $71.70 2
Genentech, Inc. $69.96 1
Evofem Biosciences, Inc. $23.06 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS J GEORGE

NPI 1104867365 · CMS profile ID 321938

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104867365?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104867365?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104867365?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1104867365?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $299.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Evofem Biosciences, Inc. $23.0608/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 976107295 CMS
MAYNE PHARMA COMMERCIAL LLC $37.1607/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060835327 CMS
Genentech, Inc. $69.9606/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040579939 CMS
MAYNE PHARMA COMMERCIAL LLC $34.5402/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060835325 CMS
AstraZeneca Pharmaceuticals LP $134.7001/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025024287 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,139.61 16
PY2020 $806.00 2
PY2021 $5,850.00 2
PY2022 $5,602.52 7
PY2023 $299.42 5
PY2024 $1,820.00 3
PY2025 $2,260.64 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $507,584.60 83
PY2024 Recipient $2,598.05 11
PY2024 Principal investigator $596,039.96 28
PY2023 Principal investigator $1,130,234.11 90
PY2022 Principal investigator $1,675,365.46 75
PY2021 Principal investigator $2,129,940.43 124
PY2020 Principal investigator $2,169,106.03 143
PY2019 Principal investigator $2,064,075.98 203

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $22,038.07 12/31/2023 Non-covered Recipient Entity
University of Florida College of Medicine
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 1042535577
Principal investigator 1 Merck Sharp & Dohme LLC $155,243.49 12/31/2023 Non-covered Recipient Entity
University of Florida College of Medicine
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 1042536243
Principal investigator 1 Merck Sharp & Dohme LLC $127,656.60 12/18/2023 Non-covered Recipient Entity
University of Florida College of Medicine
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 1042535567
Principal investigator 1 Seagen Inc. $988.00 11/29/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824901
Principal investigator 1 Seagen Inc. $227.50 11/29/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995825589
Principal investigator 1 Seagen Inc. $1,716.00 10/25/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824891
Principal investigator 1 Seagen Inc. $823.13 10/18/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824911
Principal investigator 1 Seagen Inc. $1,092.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824921
Principal investigator 1 Seagen Inc. $520.00 10/18/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824973
Principal investigator 1 Seagen Inc. $2,440.10 10/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824931
Principal investigator 1 Seagen Inc. $8,320.00 09/27/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824719
Principal investigator 1 Seagen Inc. $3,211.00 09/27/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824729
Principal investigator 1 Seagen Inc. $520.00 09/13/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824709
Principal investigator 1 Seagen Inc. $1,865.50 08/30/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824749
Principal investigator 1 Seagen Inc. $9,122.10 08/09/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824667
Principal investigator 1 Seagen Inc. $9,438.00 08/02/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824677
Principal investigator 1 Seagen Inc. $1,092.00 08/02/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824687
Principal investigator 1 Seagen Inc. $1,144.00 08/02/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824699
Principal investigator 1 Seagen Inc. $1,950.00 07/26/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824739
Principal investigator 1 Genentech, Inc. $5,538.00 06/26/2023 Non-covered Recipient Entity
University of Florida
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1040584125
Principal investigator 1 Incyte Corporation $488.00 06/21/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1061096511
Principal investigator 1 Incyte Corporation $650.00 06/21/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1061096513
Principal investigator 1 Incyte Corporation $228.00 06/21/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1061096515
Principal investigator 1 Incyte Corporation $1,731.60 06/21/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1061096517
Principal investigator 1 Seagen Inc. $3,685.50 06/07/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824345
Principal investigator 1 Seagen Inc. $2,522.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824355
Principal investigator 1 Seagen Inc. $4,628.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824365
Principal investigator 1 Seagen Inc. $4,340.70 06/07/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824377
Principal investigator 1 Seagen Inc. $6,925.00 06/07/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824387
Principal investigator 1 Seagen Inc. $4,186.00 05/30/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824283
Principal investigator 1 Seagen Inc. $227.50 05/30/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824293
Principal investigator 1 Seagen Inc. $6,570.20 05/30/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824305
Principal investigator 1 Seagen Inc. $1,170.00 05/30/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824337
Principal investigator 1 Seagen Inc. $227.50 05/30/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824449
Principal investigator 1 Seagen Inc. $227.50 05/30/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824455
Principal investigator 1 Seagen Inc. $5,044.00 05/24/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824315
Principal investigator 1 Seagen Inc. $54,840.20 05/24/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824325
Principal investigator 1 Seagen Inc. $4,806.10 05/24/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824417
Principal investigator 1 Seagen Inc. $975.00 05/24/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824429
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,000.00 05/20/2023 Non-covered Recipient Entity
NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT FOUNDATION, INC
A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer No dispute reported 06/30/2026 991136713
Principal investigator 1 Seagen Inc. $4,900.00 05/17/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824439
Principal investigator 1 Seagen Inc. $10,797.80 05/10/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824397
Principal investigator 1 Seagen Inc. $975.00 05/10/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824409
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $37,786.00 05/09/2023 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 1045024809
Principal investigator 1 Celgene Corporation $33,912.00 04/14/2023 Non-covered Recipient Entity
University Of Florida Board Of Trustees
Phase III Study - PANC-003 - A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1026489819
Principal investigator 1 GlaxoSmithKline, LLC. $15,131.02 04/05/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A SCREENING PROTOCOL TO SUPPORT PRELIMINARY ELIGIBILITY FOR CLINICAL T No dispute reported 06/30/2026 1006145353
Principal investigator 1 Seagen Inc. $7,833.80 03/29/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824155
Principal investigator 1 Seagen Inc. $4,754.10 03/29/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824165
Principal investigator 1 GlaxoSmithKline, LLC. $94,541.44 03/27/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE II TRIAL OF THE PARP INHIBITOR, NIRAPARIB, IN BAP1 AND OTHER D No dispute reported 06/30/2026 1006145343
Principal investigator 1 GlaxoSmithKline, LLC. $24,828.76 03/27/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE II TRIAL OF THE PARP INHIBITOR, NIRAPARIB, IN BAP1 AND OTHER D No dispute reported 06/30/2026 1006145693
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $26,990.00 03/27/2023 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 1045024515
Principal investigator 1 Seagen Inc. $65.00 03/22/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824253
Principal investigator 1 Seagen Inc. $6,680.70 03/22/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824263
Principal investigator 1 Genentech, Inc. $2,255.50 03/20/2023 Non-covered Recipient Entity
University of Florida
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1040584141
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $37,786.00 03/20/2023 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 1045024456
Principal investigator 1 Seagen Inc. $3,796.00 03/15/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824245
Principal investigator 1 Celgene Corporation $4,896.00 03/14/2023 Non-covered Recipient Entity
Uf Health Clinical Science Translational Science Institute
Phase III Study - PANC-003 - A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1026489715
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $188.40 03/08/2023 Non-covered Recipient Entity
University Of Florida Board Of Trustees
A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer No dispute reported 06/30/2026 1027457113
Principal investigator 1 Genentech, Inc. $890.50 03/06/2023 Non-covered Recipient Entity
University of Florida
PHASE I DOSE ESCALATION STUDY OF RO7444973 ON SOLID TUMOURS No dispute reported 06/30/2026 1040584205
Principal investigator 1 Seagen Inc. $10,348.00 03/03/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824225
Principal investigator 1 Seagen Inc. $3,419.00 03/03/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824235
Principal investigator 1 Genentech, Inc. $5,950.00 02/24/2023 Non-covered Recipient Entity
University of Florida
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1040584157
Principal investigator 1 Seagen Inc. $730.60 02/22/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824043
Principal investigator 1 Seagen Inc. $730.60 02/22/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824053
Principal investigator 1 Seagen Inc. $227.50 02/22/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824063
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 02/09/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A SCREENING PROTOCOL TO SUPPORT PRELIMINARY ELIGIBILITY FOR CLINICAL T No dispute reported 06/30/2026 1006145309
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 02/09/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A SCREENING PROTOCOL TO SUPPORT PRELIMINARY ELIGIBILITY FOR CLINICAL T No dispute reported 06/30/2026 1006145321
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 02/09/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A SCREENING PROTOCOL TO SUPPORT PRELIMINARY ELIGIBILITY FOR CLINICAL T No dispute reported 06/30/2026 1006145333
Principal investigator 1 GlaxoSmithKline, LLC. $1,560.00 02/09/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A SCREENING PROTOCOL TO SUPPORT PRELIMINARY ELIGIBILITY FOR CLINICAL T No dispute reported 06/30/2026 1006145703
Principal investigator 1 Seagen Inc. $4,722.00 02/03/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824133
Principal investigator 1 Seagen Inc. $4,565.00 02/03/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824145
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $53,980.00 01/30/2023 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 1045024399
Principal investigator 1 Novartis Pharmaceuticals Corporation $45,246.00 01/26/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
Appendix F to the Precision Promise Master Protocol: Canakinumab and Spartalizumab in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Metastatic Pancreatic Cancer No dispute reported 06/30/2026 1017207353
Principal investigator 1 Genentech, Inc. $9,798.00 01/25/2023 Non-covered Recipient Entity
University of Florida
PHASE I DOSE ESCALATION STUDY OF RO7444973 ON SOLID TUMOURS No dispute reported 06/30/2026 1040584229
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $53,980.00 01/11/2023 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 1045024323
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $44,082.50 01/10/2023 Non-covered Recipient Entity
Uf Health Medical Oncology - Davis Cancer Pavilion
Phase I/IIA 2L/3L CRC MSS KRAS Nivo/MEK Combo (trametinib/Novartis) No dispute reported 06/30/2026 1027475033
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $37,786.00 01/10/2023 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 1045024307
Principal investigator 1 Seagen Inc. $4,722.00 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824073
Principal investigator 1 Seagen Inc. $227.50 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824083
Principal investigator 1 Seagen Inc. $730.60 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824093
Principal investigator 1 Seagen Inc. $4,565.00 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824103
Principal investigator 1 Seagen Inc. $4,565.00 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824113
Principal investigator 1 Seagen Inc. $4,625.00 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 995824123
Principal investigator 1 Seagen Inc. $10,348.00 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824175
Principal investigator 1 Seagen Inc. $5,378.10 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824185
Principal investigator 1 Seagen Inc. $5,378.10 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824195
Principal investigator 1 Seagen Inc. $11,181.30 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824205
Principal investigator 1 Seagen Inc. $11,181.30 01/04/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors No dispute reported 06/30/2026 995824215
Principal investigator 1 TerSera Therapeutics LLC $4,655.70 01/03/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 1052673587
Principal investigator 1 TerSera Therapeutics LLC $325.00 01/03/2023 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 1052673589